Another PD-L1 and TGF-β dual antibody, SHR-1701, is in various stages of clinical trials for a variety of malignancies, and their results are promising and may provide a new direction for immunotherapy in ESCC. Here, CD274 is linked to esophageal squamous cell carcinoma.